123 related articles for article (PubMed ID: 1357070)
1. Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
Trainer PJ; Kirk JM; Savage MO; Grossman AB; Besser GM
J Endocrinol; 1992 Sep; 134(3):513-7. PubMed ID: 1357070
[TBL] [Abstract][Full Text] [Related]
2. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition.
del Balzo P; Salvatori R; Cappa M; Gertner JM
Clin Endocrinol (Oxf); 1990 Nov; 33(5):605-12. PubMed ID: 1979261
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
[TBL] [Abstract][Full Text] [Related]
4. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
[TBL] [Abstract][Full Text] [Related]
5. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
[TBL] [Abstract][Full Text] [Related]
6. Radiation and neuroregulatory control of growth hormone secretion.
Ogilvy-Stuart AL; Wallace WH; Shalet SM
Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
[TBL] [Abstract][Full Text] [Related]
7. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
[TBL] [Abstract][Full Text] [Related]
8. The late growth hormone rise induced by oral glucose is enhanced by cholinergic stimulation with pyridostigmine in normal subjects.
Valcavi R; Zini M; Davoli S; Portioli I
Clin Endocrinol (Oxf); 1992 Oct; 37(4):360-4. PubMed ID: 1483293
[TBL] [Abstract][Full Text] [Related]
9. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
[TBL] [Abstract][Full Text] [Related]
10. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
Borges MH; Castro RC; Kater CE; Lengyel AM
Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
[TBL] [Abstract][Full Text] [Related]
11. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
Ismail IS; Scanlon MF; Peters JR
Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
[TBL] [Abstract][Full Text] [Related]
13. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
14. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
Ross RJ; Tsagarakis S; Grossman A; Nhagafoong L; Touzel RJ; Rees LH; Besser GM
Clin Endocrinol (Oxf); 1987 Dec; 27(6):727-33. PubMed ID: 2901302
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
16. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid-induced growth hormone secretion in normal and obese subjects.
Muruais C; Cordido F; Morales MJ; Casanueva FF; Diéguez C
Clin Endocrinol (Oxf); 1991 Dec; 35(6):485-90. PubMed ID: 1769129
[TBL] [Abstract][Full Text] [Related]
18. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
[TBL] [Abstract][Full Text] [Related]
19. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
Friend K; Iranmanesh A; Login IS; Veldhuis JD
Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
[TBL] [Abstract][Full Text] [Related]
20. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
Pinto AC; Finamor FE; Lengyel AM
Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]